Logo image of NAUT

NAUTILUS BIOTECHNOLOGY INC (NAUT) Stock Fundamental Analysis

NASDAQ:NAUT - Nasdaq - US63909J1088 - Common Stock - Currency: USD

0.8816  -0.05 (-4.9%)

After market: 0.909 +0.03 (+3.11%)

Fundamental Rating

2

NAUT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 55 industry peers in the Life Sciences Tools & Services industry. NAUT has a great financial health rating, but its profitability evaluates not so good. NAUT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NAUT had negative earnings in the past year.
NAUT had a negative operating cash flow in the past year.
NAUT had negative earnings in each of the past 5 years.
NAUT had a negative operating cash flow in each of the past 5 years.
NAUT Yearly Net Income VS EBIT VS OCF VS FCFNAUT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

With a Return On Assets value of -29.16%, NAUT is not doing good in the industry: 74.55% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -33.91%, NAUT is doing worse than 61.82% of the companies in the same industry.
Industry RankSector Rank
ROA -29.16%
ROE -33.91%
ROIC N/A
ROA(3y)-22.18%
ROA(5y)-19.51%
ROE(3y)-25.43%
ROE(5y)-22%
ROIC(3y)N/A
ROIC(5y)N/A
NAUT Yearly ROA, ROE, ROICNAUT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NAUT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NAUT Yearly Profit, Operating, Gross MarginsNAUT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, NAUT has more shares outstanding
The number of shares outstanding for NAUT has been increased compared to 5 years ago.
There is no outstanding debt for NAUT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NAUT Yearly Shares OutstandingNAUT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
NAUT Yearly Total Debt VS Total AssetsNAUT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -0.10, we must say that NAUT is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of NAUT (-0.10) is worse than 74.55% of its industry peers.
NAUT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.1
ROIC/WACCN/A
WACCN/A
NAUT Yearly LT Debt VS Equity VS FCFNAUT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 17.40 indicates that NAUT has no problem at all paying its short term obligations.
NAUT's Current ratio of 17.40 is amongst the best of the industry. NAUT outperforms 100.00% of its industry peers.
A Quick Ratio of 17.40 indicates that NAUT has no problem at all paying its short term obligations.
The Quick ratio of NAUT (17.40) is better than 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 17.4
Quick Ratio 17.4
NAUT Yearly Current Assets VS Current LiabilitesNAUT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

0

3. Growth

3.1 Past

NAUT shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.82%.
EPS 1Y (TTM)1.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, NAUT will show a decrease in Earnings Per Share. The EPS will decrease by -5.99% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-7.17%
EPS Next 2Y-14.02%
EPS Next 3Y-5.99%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NAUT Yearly Revenue VS EstimatesNAUT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 20M 40M 60M
NAUT Yearly EPS VS EstimatesNAUT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NAUT. In the last year negative earnings were reported.
Also next year NAUT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NAUT Price Earnings VS Forward Price EarningsNAUT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NAUT Per share dataNAUT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

A cheap valuation may be justified as NAUT's earnings are expected to decrease with -5.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.02%
EPS Next 3Y-5.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NAUT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NAUTILUS BIOTECHNOLOGY INC

NASDAQ:NAUT (5/14/2025, 8:00:02 PM)

After market: 0.909 +0.03 (+3.11%)

0.8816

-0.05 (-4.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)04-29 2025-04-29/bmo
Earnings (Next)07-28 2025-07-28/bmo
Inst Owners38.96%
Inst Owner Change-0.07%
Ins Owners32.3%
Ins Owner Change0.24%
Market Cap111.21M
Analysts76.36
Price Target1.79 (103.04%)
Short Float %1.22%
Short Ratio5.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.02%
Min EPS beat(2)15.27%
Max EPS beat(2)22.76%
EPS beat(4)4
Avg EPS beat(4)15.96%
Min EPS beat(4)9.5%
Max EPS beat(4)22.76%
EPS beat(8)8
Avg EPS beat(8)17.19%
EPS beat(12)12
Avg EPS beat(12)20.21%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.67%
PT rev (3m)-40%
EPS NQ rev (1m)0%
EPS NQ rev (3m)17.27%
EPS NY rev (1m)0%
EPS NY rev (3m)22.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.53
P/tB 0.53
EV/EBITDA N/A
EPS(TTM)-0.54
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)-0.47
OCFYN/A
SpS0
BVpS1.65
TBVpS1.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.16%
ROE -33.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-22.18%
ROA(5y)-19.51%
ROE(3y)-25.43%
ROE(5y)-22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 107.44%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.4
Quick Ratio 17.4
Altman-Z -0.1
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)143.23%
Cap/Depr(5y)156.36%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
EPS Next Y-7.17%
EPS Next 2Y-14.02%
EPS Next 3Y-5.99%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-6.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.63%
EBIT Next 3Y-9.03%
EBIT Next 5Y-3.57%
FCF growth 1Y-13.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-14.38%
OCF growth 3YN/A
OCF growth 5YN/A